Trials / Recruiting
RecruitingNCT05595590
Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer
Phase II Trial of Pulsed Radiotherapy Combined With Tislelizumab in Patients With Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the efficacy and safety of pulsed radiotherapy given concomitantly with Tislelizumab and as maintenance therapy in participants with locoregionally recurrent head and neck squamous cell carcinoma ( HNSCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tislelizumab | Administered as an intravenous (IV) infusion 200mg every 3 weeks (Q3W) |
| RADIATION | Pulse radiation | 66-70Gy/33-35Fx, 2Gy/Fx. |
Timeline
- Start date
- 2022-10-20
- Primary completion
- 2024-10-19
- Completion
- 2026-10-19
- First posted
- 2022-10-27
- Last updated
- 2022-10-27
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05595590. Inclusion in this directory is not an endorsement.